Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Spiriva Respimat
tiotropium pMDI · 1 trial · 1 indication
noncompartmental analysis
| Arm | Type | Description |
|---|---|---|
| Test Product 1 | EXPERIMENTAL | tiotropium pMDI 2 inhalations |
| Test Product 2 | EXPERIMENTAL | tiotropium pMDI 2 inhalations |
| Test Product 3 | EXPERIMENTAL | tiotropium pMDI 2 inhalations |
| Test Product 4 | EXPERIMENTAL | tiotropium pMDI 2 inhalations |
| Commercial Product | ACTIVE_COMPARATOR | tiotropium Respimat 2 inhalations |
| Name | Type | Description |
|---|---|---|
| tiotropium pMDI | DRUG | inhalation |
Inclusion Criteria: * Healthy Volunteer * Willing and able to give informed consent * Willing to withhold all alcoholic beverages for 48 hours and all xanthine- containing foods and beverages for 24 hours prior to reporting to clinic * Subjects must agree to use an adequate method of contraception ...
Tiotropium pMDI is an investigational pressurized metered dose inhaler formulation of tiotropium, a small molecule drug being developed by Solventum Corporation. It is in Phase 1 clinical development. The specific medical conditions it is intended to treat have not been disclosed.
Tiotropium pMDI targets CHRM3, the muscarinic acetylcholine receptor M3. It acts as an antagonist at this receptor. By blocking CHRM3, the drug is designed to interfere with cholinergic signaling, which is a mechanism relevant to airway function.
Tiotropium pMDI is being developed by Solventum Corporation, which trades under the ticker SOLV. The company is responsible for the clinical development of this inhaler product.
Tiotropium pMDI is in Phase 1 clinical development. It is an investigational product and has not been approved by the FDA. One early Phase 1 trial has been completed, and no active trials are currently listed.
Tiotropium pMDI has been studied in one completed clinical trial, NCT03155204, titled Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With A Reference Product. The trial enrolled 46 healthy volunteers in the United Kingdom and was active-controlled and randomized.